Precision Medicine Online’s Post

Exciting research led by Tianyi Liu, PhD and team showcasing the transformation of glioblastoma cells into an inducible dendritic cell phenotype for enhanced CD8 T cell activation and anti-cancer effects. The pivotal question remains: how can this remarkable progress be effectively applied in clinical settings? #Research #CancerTreatment #Innovation #genetherapy #cellandgenetherapy #cancerimmunology

#SERSomes for metabolic phenotyping and prostate cancer diagnosis:- •Molecular phenotypic variations in metabolites offer the promise of rapid profiling of physiological and pathological states for diagnosis, monitoring, and prognosis. •Since present methods are expensive, time-consuming, and still not sensitive enough, there is an urgent need for approaches that can interrogate complex biological fluids at a system-wide level. •Here, we introduce hyperspectral surface-enhanced Raman spectroscopy (SERS) to profile microliters of biofluidic metabolite extraction in 15 min with a spectral set, SERSome, that can be used to describe the structures and functions of various molecules produced in the biofluid at a specific time via SERS characteristics. •The metabolite differences of various biofluids, including cell culture medium and human serum, are successfully profiled, showing a diagnosis accuracy of 80.8% on the internal test set and 73% on the external validation set for prostate cancer, discovering potential biomarkers, and predicting the tissue-level pathological aggressiveness. SERSomes offer a promising methodology for metabolic phenotyping. #highlights :- •SERSomes profile the metabolic phenotypes of various biofluids. •SERSomes improve diagnostic accuracy with deep learning models. •SERSomes facilitate metabolite biomarker discovery.

#PaperoftheDay: "Notch1 signaling pathway promotes growth and metastasis of gastric cancer via modulating CDH5" DOI ⬇️ https://lnkd.in/egP4ai8M #aging #gastriccancer #research #openaccess #peerreview #publishing

𝐃𝐢𝐯𝐢𝐧𝐠 𝐢𝐧𝐭𝐨 Personalis, Inc.: 𝐘𝐨𝐮𝐫 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐏𝐨𝐰𝐞𝐫𝐡𝐨𝐮𝐬𝐞🧬 As we continue our exploration of the top 5 molecular diagnostics companies to watch in 2024, today we turn our spotlight to Personalis, Inc. (PSNL). This company isn't just riding the personalised medicine wave – they're building the surfboard! 🏄 𝐖𝐡𝐚𝐭 𝐦𝐚𝐤𝐞𝐬 Personalis, Inc. 𝐭𝐢𝐜𝐤? ⏰ Their claim to fame is the Personalis NeXT Platform, a comprehensive tool that analyses a patient's DNA, RNA, and protein data to provide tailored insights for treatment decisions. Think of it as a high-tech crystal ball for doctors, offering a glimpse into the most effective therapies for each individual patient. 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬 𝐢𝐧 𝐀𝐜𝐭𝐢𝐨𝐧 💊 𝑷𝒓𝒆𝒄𝒊𝒔𝒊𝒐𝒏 𝑶𝒏𝒄𝒐𝒍𝒐𝒈𝒚:  Personalis helps oncologists navigate the complex world of cancer treatment by identifying targeted therapies, predicting response to drugs, and monitoring tumor evolution. 𝑰𝒎𝒎𝒖𝒏𝒐-𝑶𝒏𝒄𝒐𝒍𝒐𝒈𝒚: ️They're also at the forefront of immuno-oncology, analysing a patient's immune profile to predict who might benefit from immunotherapy and how to optimise these treatments. 𝑪𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝑻𝒓𝒊𝒂𝒍𝒔: Personalis partners with biopharma companies to design and accelerate clinical trials by identifying the right patients for these studies based on their unique genomic profiles. 𝐖𝐡𝐚𝐭'𝐬 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬' 𝐆𝐫𝐨𝐰𝐭𝐡? 🌱 𝑷𝒂𝒓𝒕𝒏𝒆𝒓𝒔𝒉𝒊𝒑𝒔 𝒈𝒂𝒍𝒐𝒓𝒆: Think major collaborations with pharma giants like Roche and AstraZeneca, solidifying their position in the industry. 𝑫𝒂𝒕𝒂 𝒂𝒅𝒗𝒂𝒏𝒕𝒂𝒈𝒆: They've amassed a massive trove of genomic and clinical data, which they leverage to develop powerful algorithms and insights. 𝑭𝒐𝒄𝒖𝒔 𝒐𝒏 𝒖𝒏𝒎𝒆𝒕 𝒏𝒆𝒆𝒅𝒔: Personalis tackles challenges like late-stage cancer and resistance to therapy, where traditional approaches often fall short. 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬 𝐛𝐲 𝐭𝐡𝐞 𝐍𝐮𝐦𝐛𝐞𝐫𝐬 (2023) 🚀 -  5̳4̳%̳ ̳r̳e̳v̳e̳n̳u̳e̳ ̳g̳r̳o̳w̳t̳h̳ – impressive even in this booming market! -  O̳v̳e̳r̳ ̳1̳0̳0̳ ̳p̳a̳r̳t̳n̳e̳r̳s̳h̳i̳p̳s̳with leading cancer centers and pharma companies. -  5̳x̳ ̳i̳n̳c̳r̳e̳a̳s̳e̳ ̳i̳n̳ ̳c̳l̳i̳n̳i̳c̳a̳l̳ ̳t̳r̳i̳a̳l̳ ̳p̳a̳r̳t̳i̳c̳i̳p̳a̳t̳i̳o̳n̳ for patients using the Personalis NeXT Platform. 𝐅𝐮𝐭𝐮𝐫𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 🚀 𝑪𝒐𝒏𝒕𝒊𝒏𝒖𝒆𝒅 𝒎𝒂𝒓𝒌𝒆𝒕 𝒆𝒙𝒑𝒂𝒏𝒔𝒊𝒐𝒏: Personalis is eyeing both geographical and clinical space growth, targeting new cancer types and applications. 𝑨𝑰-𝒑𝒐𝒘𝒆𝒓𝒆𝒅 𝒂𝒅𝒗𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕𝒔: Expect even more sophisticated algorithms and insights as they harness the power of artificial intelligence. 𝑷𝒆𝒓𝒔𝒐𝒏𝒂𝒍𝒊𝒔𝒆𝒅 𝒎𝒆𝒅𝒊𝒄𝒊𝒏𝒆 𝒎𝒂𝒊𝒏𝒔𝒕𝒓𝒆𝒂𝒎𝒊𝒏𝒈: With Personalis leading the charge, personalised medicine is poised to become the standard of care, not just a dream. 💼 𝐂𝐄𝐎: Christopher Hall https://lnkd.in/e_XknAmn #moleculardiagnostics #personalisedmedicine #precisiononcology #cancercare

  The liquid biopsy market, driven by technology advancements and its non-invasive approach, is set to hit $18 billion by 2032 – It is exciting to see such promising opportunities that will push the boundaries and enable the early detection of cancer. CanSense are at the forefront of this market utilising novel techniques. Forecast: Liquid Biopsy Market to Exceed $18 Billion by 2032 | Inside Precision Medicine https://lnkd.in/eb4Y627p #CanSense #EarlyDetectionOfCancer #LiquidBioposy #BowelCancer Forecast: Liquid Biopsy Market to Exceed $18 Billion by 2032 The global liquid biopsy market will exceed $18 billion by 2032 according to a new forecast from market insights company Precedence Research.  

#Telomeres which shorten with every round of replication is extensively studied in ageing and cancer as it tips the cell survival mechanisms. Long reads such as #nanopore and #pacbio could provide more insights on the telomeric regions, which are hard access for short read platforms. 2 back to back publications (open access) on long read based telomere studies provides new insights. https://lnkd.in/geZ9B4hc https://lnkd.in/gbWwJjZa

It is exciting to be part of this market CanSense making the early detection of cancer a reality for many. #CanSense #EarlyDetectionOfCancer #LiquidBioposy #earlydetectionofbowelcancer

Discover how our AI technology is revolutionizing cancer treatment at Aichi Cancer Center. By analyzing over 1.2 million medical records, we're identifying effective drug candidates for specific gene mutations. Learn how this partnership enhances patient care: https://okt.to/ovrpL6 #HealthyLiving #AI #CancerTreatment #Healthcare #Fujitsu #FujitsuPortugal

✨ I am thrilled to announce the publication of my first first-author scientific article in Clinical and Translational Medicine ✨ The article entitled « STING-ATF3/Type I interferon crosstalk: a potential target to improve anti-tumor immunity in chemotherapy-treated urothelial carcinoma » explores the complex interactions between chemotherapy and key immune pathways and highlights a potential new strategy for targeting cold tumors. 🔍🧬 🔬 A big thanks to all the « Drug Resistance and New Cancer Treatment » group at the IRCM - Institut de Recherche en Cancérologie de Montpellier, especially my mentors Céline Gongora and Houede Nadine, and all our collaborators who made this work possible. 👏 A first significant step in my research journey, can’t wait for the new discoveries to come!🤩 Check out the article here : https://lnkd.in/eM8mXmgK #Research #ImmunoOncology #CancerResearch #STINGpathway #ColdTumors #UrothelialCancer #ATF3 #Interferon #3Dmodel #spheroids #ScientificPublication #ProudMoment

Our publication using an AI algorithm to screen for RET mutational status in H&E images from lung cancer patients is out in AI in Precision Oncology!!! We demonstrated that we could use H&E images to determine RET+ mutational status with a 100% sensitivity and >50% specificity, which were the parameters predefined for successful project completion. Thanks to Alan Jerusalmi, PhD at BioAI and Kelly Credille at Eli Lilly and Company for their persistence and hard work in getting this nice work published!!!! Ironically, I ended up doing this same type of work at Nucleai and I love it!😁 #spatialbiology #digitalpathology https://lnkd.in/e2DT9Sz9